N@N

Keller Rohrback L.L.P. Announces Investigation of Lung and Liver Problems Potentially Associated with Recalled Childrena?s and

^{Published on 2010-05-28 15:05:24 - Market Wire}
 

SEATTLE--([ BUSINESS WIRE ])--Attorney Advertising. Keller Rohrback L.L.P. ([ www.krclassaction.com ]) announces that it is investigating possible claims against Johnson & Johnson (NYSE: JNJ), and its McNeil-PCC, Inc. Division (the aCompanya), related to the Companya™s recalls of childrena™s and infantsa™ liquid medications due to the possibility that these medications cause lung and liver problems.

The Company most recently recalled the medications following an April 2010 inspection by the Food and Drug Administration (aFDAa). In the inspection report, the FDA observed the presence of Burkholderia cepaciabacteria. The FDA further observed super potent batches that contained more of the active ingredient (acetaminophen) than represented, because there was no product mixing procedure to assure uniformity and homogeneity in these medications. The Company also recalled childrena™s and infantsa™ liquid medications in September 2009, again based upon the presence ofBurkholderia cepaciabacteria.

Burkholderia cepaciabacteriacan cause pneumonia in immunocompromised individuals with an underlying lung condition. Infants and children with underlying lung conditions such as cystic fibrosis, obstructive lung disease, or chronic granulomatous disease may be particularly susceptible to pneumonia caused by thesebacteria. Burkholderia cepacia bacteriaare unfortunately resistant to some widely used antibiotics and can also survive topical antiseptics. In the worst case scenario, Burkholderia cepaciabacteriacan cause lung function to become severely compromised, leading to the patienta™s death.

Sustained use of super potent doses of acetaminophen is also a concern as taking more than the recommended dose of acetaminophen may cause liver damage.

Keller Rohrback is currently investigating possible claims against the Company pertaining to its recall of the following liquid medications:

• Tylenol^® brand Infantsa™ Drops, Childrena™s Suspensions, and Childrena™s Plus Suspensions;
• Motrin^® brand Infantsa™ Drops, Childrena™s Suspensions, and Childrena™s Cold Suspensions;
• Childrena™s Zyrtec^®; and
• Childrena™s Benadryl^®.

If you purchased any of these products and have concerns about lung or liver problems, please contact paralegal Katie Grant or attorneys Amy N.L. Hanson or Lynn Sarko at 800-776-6044 or 206-442-1556 or via email at [ consumer@kellerrohrback.com ].

Keller Rohrback, with offices in Seattle, Phoenix, and New York, has successfully pursued claims against product manufacturers and pharmaceutical companies on behalf of our injured clients, as well as achieved multi-million dollar results.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.